Johns Hopkins HIV Guide
Valganciclovir
INDICATIONS
FDA
FDA
- Treatment of CMV retinitis (AIDS).
- Prevention of CMV disease: renal, cardiac and kidney-pancreas transplant patients at high risk for CMV disease (e.g., donor positive, recipient negative).
- Not indicated in liver transplant patients.
- Prevention of CMV disease in renal and cardiac transplant patients at high risk, pediatric.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prevention of disseminated CMV disease of the contralateral eye in patients treated with intraocular ganciclovir implant (no longer manufactured).
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 16, 2023
Citation
Dzintars, Kathryn, and Paul G Auwaerter. "Valganciclovir." Johns Hopkins HIV Guide, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545261/all/Valganciclovir.
Dzintars K, Auwaerter PG. Valganciclovir. Johns Hopkins HIV Guide. 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545261/all/Valganciclovir. Accessed December 4, 2023.
Dzintars, K., & Auwaerter, P. G. (2023). Valganciclovir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545261/all/Valganciclovir
Dzintars K, Auwaerter PG. Valganciclovir [Internet]. In: Johns Hopkins HIV Guide. ; 2023. [cited 2023 December 04]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545261/all/Valganciclovir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Valganciclovir
ID - 545261
A1 - Dzintars,Kathryn,Pharm.D., BCPS
AU - Auwaerter,Paul,M.D.
Y1 - 2023/07/16/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545261/all/Valganciclovir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
